Novartis Investigative Site

Inashiki-gun, Ibaraki 300-0395

0 studies enrolling now · 2 studies all time

What they study most

Moderate to Severe Plaque-type Psoriasis

Studies at this site

• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year — Completed
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed